All In Biotech

NDA 022417 · Abbvie

Norvir

Ritonavir · Oral · Cytochrome P450 3A Inhibitor; Protease Inhibitor

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Feb 10, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,048

265 Phase 3, 24 recruiting

FAERS reports

29,122

26,508 serious, 2,649 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing NORVIR or when prescribing other medications to patients already taking NORVIR [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS See full prescribing information for complete boxed warning Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in...

What it is approved for

From the label in effect Jul 23, 2026.

NORVIR tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. NORVIR tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ) NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection ( 1 )

Mechanism: Ritonavir is an antiretroviral drug [see Microbiology ( 12.4 ) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NORVIR · RITONAVIR 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ritonavir" as an intervention, any sponsor and status, largest first.

All 1,048 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction2,561
  • foetal exposure during pregnancy2,398
  • anxiety1,622
  • pain1,573
  • emotional distress1,388
  • maternal exposure during pregnancy1,245
  • anhedonia1,235
  • nausea1,056
  • diarrhoea1,021
  • exposure during pregnancy1,015
  • renal failure951
  • fatigue906

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004569
2005619
2006798
2007909
20081,077
20091,368
20101,352
20111,246
20121,488
20131,465
20141,585
20152,154
20162,283
20171,802
20181,932
20191,715
20201,901
20211,434
20221,370
2023913
2024564
2025384
2026192

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jul 24, 2026

    Norvir, Tablet, 100 mg (NDC 0074-2340-30). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Norvir (Ritonavir)

2024 spending

$566K

Beneficiaries

266

1,508 claims

Per beneficiary

$2,129

$8.20 per unit

View as table
YearSpending
2020$2,536,814
2021$1,550,102
2022$1,128,899
2023$753,472
2024$566,195

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,917 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.